SynthesisCurrent oncology (Toronto, Ont.)2022
Uncommon
Synthesis in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Liquid biopsy in non-small cell lung cancer: a meta-analysis of state-of-the-art and future perspectives.Frontiers in genetics · 2023Pooled it
- Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing.International journal of clinical oncology · 2025Trial
- Integrating clinical outcomes with molecular simulations to guide the selection of non-classical EGFR-TKIs: A comprehensive analysis and development of treatment strategies.Experimental and therapeutic medicine · 2026Article
- Landscape of Chinese Lung Cancer Patients With Compound Mutations and Acquired Resistance Alterations: A Retrospective Study.International journal of cancer · 2026Article
- Molecular heterogeneity of ERBB2-altered cancers: A pan-cancer landscape across US and Japanese cohorts.NPJ precision oncology · 2026Article
- Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib forJTO clinical and research reports · 2026Article
- Amivantamab Plus Lazertinib in AtypicalJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Elevated plasma HSP90α as a prognostic marker in EGFR-mutant non-small cell lung cancer.Oncology letters · 2025Article
- Hsa_circ_0006006 is a potential biomarker for prognosis and cisplatin resistance in non-small cell lung cancer.Hereditas · 2025Article
- Unravelling the complexity ofTranslational lung cancer research · 2025Article
- Recent Developments in Tyrosine Kinase Inhibitor-based Nanotherapeutics for EGFR-resistant Non-small Cell Lung Cancer.Current drug delivery · 2025Review
- USP22 promotes gefitinib resistance and inhibits ferroptosis in non-small cell lung cancer by deubiquitination of MDM2.Thoracic cancer · 2024Article
- Co-Occurring Driver Genomic Alterations in Advanced Non-Small-Cell Lung Cancer (NSCLC): A Retrospective Analysis.Journal of clinical medicine · 2024Article
- Observational
- Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations inTranslational lung cancer research · 2024Article
- Uncommon and RareCancers · 2024Article
- Successful therapy of a critically ill non-small cell lung cancer patient with compound mutations inHeliyon · 2024Article
- EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.Targeted oncology · 2023Article
- [A Rare Case of Lung Adenocarcinoma with EGFR L833V/H835L Co-mutation and Literature Review].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Compound epidermal growth factor receptor (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.